Cover Image
Market Research Report

Anti-infective Agents Market Size, Share & Trend Analysis By Type (Antibacterial, Antifungal, Antiviral), By Route of Administration (Oral, Topical, IV), By Distribution Channel, And Segment Forecasts, 2019 - 2026

Published by Grand View Research, Inc. Product code 818728
Published Content info 190 Pages
Delivery time: 2-3 business days
Price
Back to Top
Anti-infective Agents Market Size, Share & Trend Analysis By Type (Antibacterial, Antifungal, Antiviral), By Route of Administration (Oral, Topical, IV), By Distribution Channel, And Segment Forecasts, 2019 - 2026
Published: March 25, 2019 Content info: 190 Pages
Description

The global anti-infective agents market size is expected to reach over USD 144.8 billion by 2026 according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 3.4% during the forecast period. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.

Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongstpeople regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

Further key findings from the report suggest:

  • Antiviral was estimated to be the largest segment with a market share of 48.8% in 2018 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
  • Antibacterial segment is anticipated to register the fastest CAGR of 4.0% during the forecast period, as antibacterial is the first line of treatment for a large range of infections. Increased prescription and accessibility of antibacterial due to their over-the-counter status is anticipated to further drive the segment
  • Development of combination drugs to treat and prevent serious and life-threatening infections is expected to propel the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, a comprehensive treatment regimen inclusive of four drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record
  • Oral route of administration was estimated to be the largest segment in 2018 owing to new product development and presence of strong product pipeline
  • Hospital pharmacy led the anti-infective agents market in 2018 while e-commerce is expected to be the fastest growing segment during the forecast period
  • North America was one of the leading regions in terms of revenue in 2018. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers
  • Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients
  • Some of the major companies operating in this market are Abbott; Gilead Sciences, Inc.; Bristol-Myers Squibb Company; Merck & Co., Inc.; Bayer AG; AstraZeneca; Boehringer Ingelheim; and Novartis AG.
  • Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in 2015, ReViral received funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.
Table of Contents
Product Code: 978-1-68038-973-9

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Market segmentation & scope
  • 1.2. Market definition
  • 1.3. Information procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources & third-party perspectives
    • 1.3.4. Primary research
  • 1.4. Information analysis
    • 1.4.1. Data analysis models
  • 1.5. Market formulation & data visualization
  • 1.6. Data validation & publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Anti-infective Agents Market Variables, Trends & Scope

  • 3.1. Anti-infective agents Market Lineage outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Pipeline Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
      • 3.4.1.1. Growing geriatric population base
      • 3.4.1.2. Growing prevalence of target diseases such as hospital acquired infections, STIs, and respiratory viruses
      • 3.4.1.3. Increase in collaborative development efforts
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. Development of multi-drug resistant organisms
      • 3.4.2.2. High R&D cost
  • 3.5. Anti-infective agents Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier Power: Low due to large number of manufacturers
      • 3.5.1.2. Buyer Power: Moderate due to availability of several generic products
      • 3.5.1.3. Substitution Threat: High due to presence external substitutes
      • 3.5.1.4. Threat from new entrant: Moderate due to high investments required in R&D and manufacturing
      • 3.5.1.5. Competitive rivalry: High due to rigorous competition among key players
  • 3.6. PESTEL Analysis
    • 3.6.1. Political Landscape
    • 3.6.2. Environmental Landscape
    • 3.6.3. Social Landscape
    • 3.6.4. Technology Landscape
    • 3.6.5. Legal Landscape
  • 3.7. Major Deals & Strategic Alliances Analysis
    • 3.7.1. Joint Ventures
    • 3.7.2. Mergers & Acquisitions
    • 3.7.3. Licensing & Partnership
    • 3.7.4. Technology Collaborations
    • 3.7.5. Strategic Divestments

Chapter 4. Anti-infective Agents Market - Competitive Analysis

  • 4.1. Recent developments & impact analysis, by key market participants
  • 4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 4.3. Public Companies
    • 4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 4.3.2. Company Market Share/Ranking, by region
    • 4.3.3. Competitive Dashboard Analysis
    • 4.3.4. Market Differentiators
    • 4.3.5. Synergy Analysis: Major Deals & Strategic Alliances
  • 4.4. Private Companies
    • 4.4.1. List of key emerging companies
    • 4.4.2. Regional network map
    • 4.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)

Chapter 5. Anti-infective Agents Market: Type Estimates & Trend Analysis

  • 5.1. Definitions & Scope
  • 5.2. Type market share analysis, 2018 & 2026
  • 5.3. Type Dashboard
  • 5.4. Global Anti-infective agents Market, by Type, 2013 to 2026
  • 5.5. Market Size & Forecasts and Trend Analyses, 2013 to 2026 for the following,
    • 5.5.1. Antibacterial by drug class
      • 5.5.1.1. Antibacterial market, 2013 - 2026 (USD Billion)
      • 5.5.1.2. Cephalosporins
      • 5.5.1.2.1. Cephalosporins market, 2013 - 2026 (USD Billion)
      • 5.5.1.3. Penicillin
      • 5.5.1.3.1. Penicillin market, 2013 - 2026 (USD Billion)
      • 5.5.1.4. Fluoroquinolones
      • 5.5.1.4.1. Fluoroquinolones market, 2013 - 2026 (USD Billion)
      • 5.5.1.5. Macrolides
      • 5.5.1.5.1. Macrolides market, 2013 - 2026 (USD Billion)
      • 5.5.1.6. Carbapenem
      • 5.5.1.6.1. Carbapenem market, 2013 - 2026 (USD Billion)
      • 5.5.1.7. Others
      • 5.5.1.7.1. Others market, 2013 - 2026 (USD Billion)
    • 5.5.2. Antibacterial by route of administration
      • 5.5.2.1. Topical
      • 5.5.2.1.1. Topical market, 2013 - 2026 (USD Billion)
      • 5.5.2.2. Oral
      • 5.5.2.2.1. Oral market, 2013 - 2026 (USD Billion)
      • 5.5.2.3. IV
      • 5.5.2.3.1. IV market, 2013 - 2026 (USD Billion)
      • 5.5.2.4. Others
      • 5.5.2.4.1. Others market, 2013 - 2026 (USD Billion)
    • 5.5.3. Antifungal by drug class
      • 5.5.3.1. Antifungal market, 2013 - 2026 (USD Billion)
      • 5.5.3.2. Azoles
      • 5.5.3.2.1. Azoles market, 2013 - 2026 (USD Billion)
      • 5.5.3.3. Echinocandins
      • 5.5.3.3.1. Echinocandins market, 2013 - 2026 (USD Billion)
      • 5.5.3.4. Polyenes
      • 5.5.3.4.1. Polyenes market, 2013 - 2026 (USD Billion)
      • 5.5.3.5. Others
      • 5.5.3.5.1. Others market, 2013 - 2026 (USD Billion)
    • 5.5.4. Antifungal by route of administration
      • 5.5.4.1. Antifungal market, 2013 - 2026 (USD Billion)
      • 5.5.4.2. Topical
      • 5.5.4.2.1. Topical market, 2013 - 2026 (USD Billion)
      • 5.5.4.3. Oral
      • 5.5.4.3.1. Oral market, 2013 - 2026 (USD Billion)
      • 5.5.4.4. IV
      • 5.5.4.4.1. IV market, 2013 - 2026 (USD Billion)
      • 5.5.4.5. Others
      • 5.5.4.5.1. Others market, 2013 - 2026 (USD Billion)
    • 5.5.5. Antiviral by route of administration
      • 5.5.5.1. Antiviral market, 2013 - 2026 (USD Billion)
      • 5.5.5.2. Topical
      • 5.5.5.2.1. Topical market, 2013 - 2026 (USD Billion)
      • 5.5.5.3. Oral
      • 5.5.5.3.1. Oral market, 2013 - 2026 (USD Billion)
      • 5.5.5.4. IV
      • 5.5.5.4.1. IV market, 2013 - 2026 (USD Billion)
      • 5.5.5.5. Others
      • 5.5.5.5.1. Others market, 2013 - 2026 (USD Billion)

Chapter 6. Anti-infective Agents Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Definitions & Scope
  • 6.2. Route of administration market share analysis, 2018 & 2026
  • 6.3. Route of Administration Dashboard
  • 6.4. Global Anti-infective agents Market, by Route of Administration, 2013 to 2026
  • 6.5. Market Size & Forecasts and Trend Analyses, 2013 to 2026 for the following,
  • 6.6. Topical
    • 6.6.1. Topical market, 2013 - 2026 (USD Billion)
  • 6.7. 'Oral
    • 6.7.1. Oral market, 2013 - 2026 (USD Billion)
  • 6.8. Intravenous (IV)
    • 6.8.1. IV market, 2013 - 2026 (USD Billion)
  • 6.9. Others
    • 6.9.1. Others market, 2013 - 2026 (USD Billion)

Chapter 7. Anti-infective Agents Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Definitions & Scope
  • 7.2. Distribution channel market share analysis, 2018 & 2026
  • 7.3. Distribution Channel Dashboard
  • 7.4. Global Anti-infective Agents Market, by Distribution Channel, 2013 to 2026
  • 7.5. Market Size & Forecasts and Trend Analyses, 2013 to 2026 for the following,
  • 7.6. Hospital Pharmacy
    • 7.6.1. Hospital Pharmacy market, 2013 - 2026 (USD Billion)
  • 7.7. Retail Pharmacy
    • 7.7.1. Retail Pharmacy market, 2013 - 2026 (USD Billion)
  • 7.8. Specialty Pharmacy
    • 7.8.1. Specialty Pharmacy market, 2013 - 2026 (USD Billion)
  • 7.9. E-commerce
    • 7.9.1. E-commerce market, 2013 - 2026 (USD Billion)
  • 7.10. Others
    • 7.10.1. Others market, 2013 - 2026 (USD Billion)

Chapter 8. Anti-infective Agents Market: Regional Estimates & Trend analysis

  • 8.1. Regional Market Snapshot
  • 8.2. Regional Market Share and Leading Players, 2018
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 8.3.1. North America
    • 8.3.2. Europe
    • 8.3.3. Asia Pacific
    • 8.3.4. Latin America
    • 8.3.5. Middle East & Africa
  • 8.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
  • 8.5. North America
    • 8.5.1. North America market, 2013 - 2026 (USD Billion)
    • 8.5.2. U.S.
      • 8.5.2.1. U.S. market, 2013 - 2026 (USD Billion)
    • 8.5.3. Canada
      • 8.5.3.1. Canada market, 2013 - 2026 (USD Billion)
  • 8.6. Europe
    • 8.6.1. Europe market, 2013 - 2026 (USD Billion)
    • 8.6.2. U.K.
      • 8.6.2.1. U.K. market, 2013 - 2026 (USD Billion)
    • 8.6.3. Germany
      • 8.6.3.1. Germany market, 2013 - 2026 (USD Billion)
    • 8.6.4. Spain
      • 8.6.4.1. Spain market, 2013 - 2026 (USD Billion)
    • 8.6.5. France
      • 8.6.5.1. France market, 2013 - 2026 (USD Billion)
    • 8.6.6. Italy
      • 8.6.6.1. Italy market, 2013 - 2026 (USD Billion)
    • 8.6.7. Russia
      • 8.6.7.1. Russia market, 2013 - 2026 (USD Billion)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific market, 2013 - 2026 (USD Billion)
    • 8.7.2. China
      • 8.7.2.1. China market, 2013 - 2026 (USD Billion)
    • 8.7.3. Japan
      • 8.7.3.1. Japan market, 2013 - 2026 (USD Billion)
    • 8.7.4. India
      • 8.7.4.1. India market, 2013 - 2026 (USD Billion)
    • 8.7.5. South Korea
      • 8.7.5.1. South Korea market, 2013 - 2026 (USD Billion)
    • 8.7.6. Singapore
      • 8.7.6.1. Singapore market, 2013 - 2026 (USD Billion)
    • 8.7.7. Australia
      • 8.7.7.1. Australia market, 2013 - 2026 (USD Billion)
  • 8.8. Latin America
    • 8.8.1. Latin America market, 2013 - 2026 (USD Billion)
    • 8.8.2. Brazil
      • 8.8.2.1. Brazil market, 2013 - 2026 (USD Billion)
    • 8.8.3. Mexico
      • 8.8.3.1. Mexico market, 2013 - 2026 (USD Billion)
    • 8.8.4. Argentina
      • 8.8.4.1. Argentina market, 2013 - 2026 (USD Billion)
  • 8.9. Middle East Africa (MEA)
    • 8.9.1. MEA market, 2013 - 2026 (USD Billion)
    • 8.9.2. South Africa
      • 8.9.2.1. South Africa market, 2013 - 2026 (USD Billion)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Saudi Arabia market, 2013 - 2026 (USD Billion)
    • 8.9.4. UAE
      • 8.9.4.1. UAE market, 2013 - 2026 (USD Billion)

Chapter 9. Company Profiles

  • 9.1. Strategic Framework
    • 9.1.1. GlaxoSmithKline plc.
      • 9.1.1.1. Company overview
      • 9.1.1.2. Financial framework
      • 9.1.1.3. Product benchmarking
      • 9.1.1.4. Strategic initiatives
    • 9.1.2. Pfizer, Inc
      • 9.2.1.1. Company overview
      • 9.2.1.2. Financial framework
      • 9.2.1.3. Product benchmarking
      • 9.2.1.4. Strategic initiatives
    • 9.1.3. Bayer AG
      • 9.3.1.1. Company overview
      • 9.3.1.2. Financial framework
      • 9.3.1.3. Product benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.1.4. Sanofi
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial framework
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.1.5. Merck & Co., Inc.
      • 9.5.1.1. Company overview
      • 9.5.1.2. Financial framework
      • 9.5.1.3. Product benchmarking
      • 9.5.1.4. Strategic initiatives
    • 9.1.6. Bristol-Myers Squibb Company
      • 9.6.1.1. Company overview
      • 9.6.1.2. Financial framework
      • 9.6.1.3. Product benchmarking
      • 9.6.1.4. Strategic initiatives
    • 9.1.7. Abbott
      • 9.7.1.1. Company overview
      • 9.7.1.2. Financial framework
      • 9.7.1.3. Product benchmarking
      • 9.7.1.4. Strategic initiatives
    • 9.1.8. Novartis AG
      • 9.8.1.1. Company overview
      • 9.8.1.2. Financial framework
      • 9.8.1.3. Product benchmarking
      • 9.8.1.4. Strategic initiatives
    • 9.1.9. Johnson & Johnson Services, Inc
      • 9.9.1.1. Company overview
      • 9.9.1.2. Financial framework
      • 9.9.1.3. Product benchmarking
      • 9.9.1.4. Strategic initiatives
    • 9.1.10. Astellas Pharma Inc
      • 9.10.1.1. Company overview
      • 9.10.1.2. Financial framework
      • 9.10.1.3. Product benchmarking
      • 9.10.1.4. Strategic initiatives
    • 9.1.11. Gilead Sciences, Inc.
      • 9.11.1.1. Company overview
      • 9.11.1.2. Financial framework
      • 9.11.1.3. Product benchmarking
      • 9.11.1.4. Strategic initiatives

List of Tables

  • TABLE 1 List of Abbreviation
  • TABLE 2 North America Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 3 North America Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 4 North America Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 5 North America Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 6 North America Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 7 North America Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 8 North America Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 9 North America Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 10 U.S. Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 11 U.S. Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 12 U.S. Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 13 U.S. Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 14 U.S. Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 15 U.S. Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 16 U.S. Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 17 U.S. Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 18 Canada Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 19 Canada Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 20 Canada Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 21 Canada Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 22 Canada Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 23 Canada Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 24 Canada Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 25 Canada Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 25 Europe Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 26 Europe Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 27 Europe Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 28 Europe Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 29 Europe Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 30 Europe Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 31 Europe Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 32 Europe Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 33 U.K. Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 34 U.K. Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 35 U.K. Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 36 U.K. Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 37 U.K. Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 38 U.K. Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 39 U.K. Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 40 U.K. Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 41 Germany Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 42 Germany Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 43 Germany Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 44 Germany Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 45 Germany Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 46 Germany Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 47 Germany Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 48 Germany Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 49 France Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 50 France Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 51 France Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 52 France Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 53 France Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 54 France Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 55 France Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 56 France Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 57 Italy Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 58 Italy Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 59 Italy Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 60 Italy Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 61 Italy Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 62 Italy Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 63 Italy Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 64 Italy Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 65 Spain Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 66 Spain Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 67 Spain Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 68 Spain Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 69 Spain Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 70 Spain Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 71 Spain Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 72 Spain Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 73 Russia Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 74 Russia Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 75 Russia Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 76 Russia Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 77 Russia Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 78 Russia Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 79 Russia Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 80 Russia Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 81 Asia Pacific Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 82 Asia Pacific Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 83 Asia Pacific Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 84 Asia Pacific Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 85 Asia Pacific Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 86 Asia Pacific Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 87 Asia Pacific Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 88 Asia Pacific Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 89 Japan Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 90 Japan Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 91 Japan Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 92 Japan Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 93 Japan Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 94 Japan Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 95 Japan Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 96 Japan Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 97 China Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 98 China Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 99 China Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 100 China Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 101 China Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 102 China Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 103 China Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 104 China Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 105 India Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 106 India Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 107 India Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 108 India Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 109 India Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 110 India Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 111 India Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 112 India Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 113 South Korea Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 114 South Korea Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 115 South Korea Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 116 South Korea Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 117 South Korea Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 118 South Korea Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 119 South Korea Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 120 South Korea Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 121 Australia Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 122 Australia Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 123 Australia Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 124 Australia Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 125 Australia Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 126 Australia Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 127 Australia Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 128 Australia Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 129 Singapore Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 130 Singapore Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 131 Singapore Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 132 Singapore Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 133 Singapore Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 134 Singapore Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 135 Singapore Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 136 Singapore Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 137 Latin America Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 138 Latin America Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 139 Latin America Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 140 Latin America Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 141 Latin America Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 142 Latin America Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 143 Latin America Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 144 Latin America Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 145 Brazil Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 146 Brazil Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 147 Brazil Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 148 Brazil Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 149 Brazil Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 150 Brazil Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 151 Brazil Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 152 Brazil Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 153 Mexico Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 154 Mexico Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 155 Mexico Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 156 Mexico Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 157 Mexico Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 158 Mexico Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 159 Mexico Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 160 Mexico Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 161 Argentina Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 162 Argentina Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 163 Argentina Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 164 Argentina Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 165 Argentina Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 166 Argentina Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 167 Argentina Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 168 Argentina Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 169 MEA Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 170 MEA Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 171 MEA Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 172 MEA Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 173 MEA Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 174 MEA Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 175 MEA Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 176 MEA Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 177 South Africa Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 178 South Africa Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 179 South Africa Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 180 South Africa Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 181 South Africa Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 182 South Africa Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 183 South Africa Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 184 South Africa Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 185 UAE Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 186 UAE Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 187 UAE Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 188 UAE Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 189 UAE Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 190 UAE Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 191 UAE Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 192 UAE Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)
  • TABLE 193 Saudi Arabia Anti-infective Agents Market, by Type, 2013 - 2026 (USD Billion)
  • TABLE 194 Saudi Arabia Antibacterial Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 195 Saudi Arabia Antifungal Market, by Drug Class, 2013 - 2026 (USD Billion)
  • TABLE 196 Saudi Arabia Anti-infective Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 197 Saudi Arabia Anti-bacterial Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 198 Saudi Arabia Antifungal Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 199 Saudi Arabia Antiviral Agents Market, by Route of Administration, 2013 - 2026 (USD Billion)
  • TABLE 200 Saudi Arabia Anti-infective Agents Market, by Distribution Channel, 2013 - 2026 (USD Billion)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market size and growth prospects
  • FIG. 6 Anti-infective Agents - Key Market driver analysis
  • FIG. 7 Anti-infective Agents Market - Key Market restraint analysis
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 Anti-infective Agents Market - Porter's analysis
  • FIG. 10 Anti-infective Agents Market - PESTEL analysis
  • FIG. 11 Anti-infective Agents Market type outlook key takeaways
  • FIG. 12 Anti-infective Agents Market: Type movement analysis
  • FIG. 13 Antibacterial Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 14 Cephalosporins Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 15 Penicillin Market Estimates, 2013 - 2026 (USD Billion)
  • FIG 16 Fluoroquinolones Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 17 Macrolides Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 18 Carbapenem Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 19 Others Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 20 Antifungal Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 21 Azoles Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 22 Echinocandins Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 23 Polyenes Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 24 Others Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 25 Antiviral Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 26 Anti-infective Agents Market route of administration outlook key takeaways
  • FIG. 27 Anti-infective Agents Market: Route of administration movement analysis
  • FIG. 28 Topical Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 29 Oral Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 30 IV Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 31 Others Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 32 Anti-infective Agents Market distribution channel outlook key takeaways
  • FIG. 33 Anti-infective Agents Market: Distribution channel movement analysis
  • FIG. 34 Hospital Pharmacies Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 35 Retail Pharmacies Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 36 Specialty Pharmacies Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 37 e-commerce Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 38 Others Market Estimates, 2013 - 2026 (USD Billion)
  • FIG. 39 Regional Market place: Key takeaways
  • FIG. 40 Anti-infective Agents Market: Regional movement analysis
  • FIG. 41 North America Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 42 U.S. Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 43 Canada Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 44 Europe Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 45 U.K. Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 46 Germany Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 47 France Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 48 Spain Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 49 Italy Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 50 Russia Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 51 Asia Pacific Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 52 Japan Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 53 China Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 54 India Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 55 South Korea Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 56 Singapore Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 57 Australia Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 58 Latin America Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 59 Brazil Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 60 Mexico Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 61 Argentina Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 62 MEA Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 63 South Africa Anti-infective Agents Market, 2013 - 2026 (USD Billion)
  • FIG. 64 UAE Market, 2013 - 2026 (USD Billion)
  • FIG. 65 Saudi Arabia Anti-infective agents' Market, 2013 - 2026 (USD Billion)
  • FIG. 66 Strategy Framework
Back to Top